This study is not yet accepting patients

Repurposing Riluzole for Cancer-Related Cognitive Impairment: a Pilot Trial

a study on Breast Cancer

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Irvine
Dates
study started
completion around
Principal Investigator
by Alexandre Chan (uci)
Headshot of Alexandre Chan
Alexandre Chan

Description

Summary

This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels of breast cancer survivors with cancer related cognitive impairment.

Official Title

Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Breast Cancer Patients Experiencing Cancer-Related Cognitive Impairment: an Interventional Pilot Clinical Trial

Keywords

Breast Cancer, Breast Neoplasms, Cognitive Dysfunction, Riluzole

Eligibility

You can join if…

Open to people ages 18 years and up

  • Diagnosed with breast cancer
  • Past exposure to chemotherapy, radiotherapy, and/or surgery
  • Not receiving chemotherapy, radiotherapy, and/or surgery during the study
  • ≥18 years of age
  • Perceived that cognitive function has worsened since cancer diagnosis and/or beginning of cancer treatment
  • Able to provide informed consent

You CAN'T join if...

  • Presence of metastasis
  • Unwilling to undergo neuropsychological assessments necessary for the study
  • Breastfeeding, pregnant or are planning to get pregnant during the study period
  • Suspected hypersensitivity to riluzole
  • Patients taking these potential medications/substances due to drug-drug interactions; based on specific agents listed in drug package insert (pixantrone, current smoker, abametapir, cannabis, capmatinib, methotrexate, and levoketoconazole)
  • Hepatic impairment as indicated by: AST or ALT ≥ 3x upper limit normal (ULN)

Location

  • Chao Family Comprehensive Cancer Center, University of California Irvine
    Orange California 92868 United States

Lead Scientist at University of California Health

  • Alexandre Chan (uci)
    Clinical Professor, Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences. Authored (or co-authored) 268 research publications

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Irvine
ID
NCT06580002
Phase
Phase 2 Breast Cancer Research Study
Study Type
Interventional
Participants
Expecting 34 study participants
Last Updated